New York, USA, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Irritable Bowel Syndrome Pipeline Booms as 24+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
Irritable bowel syndrome (IBS) is a group of symptoms that occur together, including repeated pain in your abdomen and changes in your bowel movements, which may be diarrhea, constipation, or both. IBS is one of the most commonly diagnosed gastrointestinal diseases.In the United States, Canada, and Isreal, IBS symptoms are 1.5 to 2 times more prevalent among women than men. Moreover, women are more likely to report abdominal pain and constipation, whereas men are more likely to report diarrhea. The prevalence of IBS also decreases with age. Increasing research and development activities by the key players in the market for the development of irritable bowel syndrome drugs are expected to drive the market growth.
DelveInsight’s 'Irritable Bowel Syndrome Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline irritable bowel syndrome therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the irritable bowel syndrome pipeline domain.
Key Takeaways from the Irritable Bowel Syndrome Pipeline Report
- DelveInsight’s irritable bowel syndrome pipeline report depicts a robust space with 24+ companies and 24+ pipeline drugs for irritable bowel syndrome treatment.
- Key irritable bowel syndrome companies include Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others are evaluating novel irritable bowel syndrome drugs candidate to improve the treatment landscape.
- Promising irritable bowel syndrome pipeline therapies in various stages of development include Olorinab, Blautix, ORP-101, BOS-589, BEKINDA, Rifamycin controlled-release, CIN 103, Crofelemer, RQ-00310941, AAT 730, and several others.
- In October 2022, Intrinsic Medicine and Phoenix Biotech Acquisition Corp. announced they have entered into a definitive business combination agreement.
- In September 2022, Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, announced the closing of a $43.5 million Series B financing.
Request a sample and discover the recent advances in irritable bowel syndrome treatment drugs @ Irritable Bowel Syndrome Pipeline Report
The irritable bowel syndrome pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage irritable bowel syndrome products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the irritable bowel syndrome pipeline landscape.
Irritable Bowel Syndrome Overview
According to the International Foundation for Gastrointestinal Disorders (IFFGD), Irritable bowel syndrome (IBS) is a disorder characterized by abdominal pain or discomfort and altered bowel habit (chronic or recurrent diarrhea, constipation, or both – either mixed or in alternation). Although the underlying pathogenesis is far from understood, etiological factors include increased epithelial hyperpermeability, dysbiosis, inflammation, visceral hypersensitivity, epigenetics and genetics, and altered brain–gut interactions. According to IFFGD, IBS affects people of all ages, even children. It affects between 25 and 45 million people in the United States. About 2 in 3 IBS sufferers are females, while 1 in 3 sufferers are males. IBS is diagnosed based on symptoms, and a distinction is made between the following subtypes of IBS: IBS with pain or discomfort and predominant constipation (IBS-C), IBS with diarrhea (IBS-D), mixed IBS (IBS-M), and unsubtyped IBS (IBS-U). IBS has a good prognosis, and the diagnosis is unlikely to change on follow-up. IBS diagnosis has evolved since its first discovery, and today the Rome IV diagnostic criteria (The Rome IV consensus is a robust standard for a clinical and research approach to functional gastrointestinal disorders) is used to diagnose IBS. Irritable bowel syndrome manifests abdominal pain/discomfort and altered bowel function. Despite affecting as many adults, a lack of understanding of etiopathogenesis and evaluation strategies results in diagnostic uncertainty and, in turn, becomes an unmet need for both the patient and the physician.
Find out more about irritable bowel syndrome treatment drugs @ Drugs for Irritable Bowel Syndrome Treatment
A snapshot of the Irritable Bowel Syndrome pipeline drugs mentioned in the report:
| Drug | Company | Phase | MoA | RoA |
| Olorinab | Pfizer | Phase II | Cannabinoid receptor CB2 agonists | Oral |
| Blautix | 4D Pharma | Phase II | Bacteria replacements; Gastrointestinal microbiome modulators | Oral |
| ORP-101 | OrphoMed Inc. | Phase II | Opioid kappa receptor antagonists; Opioid mu receptor agonists | Oral |
| BEKINDA | RedHill Biopharma | Phase II | Serotonin 3 receptor antagonists | Oral |
| BOS-589 | Boston Pharmaceuticals | Phase II | Protein tyrosine kinase inhibitors | Oral |
| Crofelemer | Napo Pharmaceuticals | Phase II | Chloride channel antagonists | Oral |
| Rifamycin controlled-release | Cosmo/Dr Falk Pharma/Salix | Phase II | DNA-directed RNA polymerase inhibitors | Oral |
Learn more about the emerging irritable bowel syndrome pipeline therapies @ Irritable Bowel Syndrome Clinical Trials
Irritable Bowel Syndrome Therapeutics Assessment
The irritable bowel syndrome pipeline report proffers an integral view of irritable bowel syndrome emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Irritable Bowel Syndrome Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Pre-clinical, Discovery, Discontinued, Inactive, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical.
- Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Cannabinoid receptor CB2 agonists, Bacteria replacements; Gastrointestinal microbiome modulators, Opioid kappa receptor antagonists; Opioid mu receptor agonists, Serotonin 3 receptor antagonists, DNA-directed RNA polymerase inhibitors
- Key Irritable Bowel Syndrome Companies: Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others.
- Key Irritable Bowel Syndrome Pipeline Therapies: Olorinab, Blautix, ORP-101, BOS-589, BEKINDA, Mesalamine, Rifamycin controlled-release, CIN 103, Crofelemer, RQ-00310941, AAT 730, and others.
Dive deep into rich insights for new drugs for irritable bowel syndrome treatment, visit @ Irritable Bowel Syndrome Drugs
Table of Contents
| 1. | Irritable Bowel Syndrome Pipeline Report Introduction |
| 2. | Irritable Bowel Syndrome Pipeline Report Executive Summary |
| 3. | Irritable Bowel Syndrome Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Irritable Bowel Syndrome Pipeline Therapeutics |
| 6. | Irritable Bowel Syndrome Pipeline: Late Stage Products (Pre-registration) |
| 7. | Irritable Bowel Syndrome Pipeline: Late Stage Products (Phase III) |
| 8. | Irritable Bowel Syndrome Pipeline: Mid-Stage Products (Phase II) |
| 9. | Irritable Bowel Syndrome Pipeline: Early Stage Products (Phase I) |
| 10. | Irritable Bowel Syndrome Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Irritable Bowel Syndrome Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Irritable Bowel Syndrome Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the irritable bowel syndrome pipeline therapeutics, reach out @ Irritable Bowel Syndrome Treatment Drugs
Related Reports
Irritable Bowel Syndrome Market
Irritable Bowel Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Irritable Bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, among others.
Irritable Bowel Syndrome Epidemiology Forecast
Irritable Bowel Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the Irritable Bowel syndrome epidemiology trends.
Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Ulcerative Colitis companies, including Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, Celgene, among others.
Ulcerative Colitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Ulcerative Colitis companies, including Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, Celgene, among others.
Peptic Ulcers Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Peptic Ulcers companies, including Daewoong Pharmaceutical, HK inno.N Corporation, PharmaKing, Recce Pharmaceuticals, Sequella Inc, Shandong Luoxin Pharmaceutical, RaQualia Pharma, Sihuan Pharmaceutical Holdings Group, Sinil Pharmaceutical, among others.
Peptic Ulcers Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Peptic Ulcers companies, including Daewoong Pharmaceutical, HK inno.N Corporation, PharmaKing, Recce Pharmaceuticals, Sequella Inc, Shandong Luoxin Pharmaceutical, RaQualia Pharma, Sihuan Pharmaceutical Holdings Group, Sinil Pharmaceutical, among others.
Other Trending Reports
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
